Key statistics dashboard for Reviva Pharmaceuticals Holdings, Inc. (RVPH). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.
Stock Data
| Price | $0.49 |
| Market Cap | $6M |
| Enterprise Value | -$19.75T |
| Exchange | OTC |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.07 |
| Price / Book | 0.00 |
| P/S | 0.00 |
| EV/EBITDA | 7.54 |
| EV/Sales | 0.00 |
| EV/FCF | 3.34 |
| P/FCF | -0.00 |
| Earnings Yield | -37819630.93% |
| FCF Yield | -94258869.97% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -64.39% |
| Return on Assets | -11.58% |
| Return on Invested Capital | -17.05% |
| Return on Capital Employed | -17.21% |
Financial Health
| Current Ratio | 3.56 |
| Quick Ratio | 3.56 |
| Cash Ratio | 3.35 |
| Debt / Equity | 0.01 |
| Debt / Assets | 0.68% |
| Net Debt / EBITDA | 7.54 |
| Interest Coverage | 891.84 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -18.12 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1151279.05 |
| Cash per share | 1505788.48 |
| FCF per share | -447930.15 |
| Tangible Book Value per share | 1151279.05 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 6 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.75 |
Related companies: ANVS · ATNM · BCAB · BTAI · CELU · EVAX · FGEN
Explore sector: Healthcare · Biotechnology
More sections of RVPH: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks